Document is current
Any future updates will be listed below
-
Authors
Fougère, Bertrand
Puisieux, François
Chevalet, Pascal
Annweiler, Cédric
Michel, Emeline
Joly, Laure
Blanc, Frédéric
Azouzi, Abdelghani EL
Desré-Follet, Valérie
Cacoub, Patrice
,
Billet, Anne-Sophie
Fiasson, Florent
Garnier-Crussard, Antoine
Goidin, Isabelle
Paccalin, Marc
Parnet, Laure
Sarasibar, Mikel
Thomas, Caroline
- License Information
-
More Information
Article History
Received: 1 August 2023
Accepted: 18 January 2024
First Online: 30 January 2024
Declarations
:
: The study conformed to the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. It was approved by a national independent Ethics Committee (“Comité de Protection des Personnes Ile de France III”) and written informed consent was obtained from all subjects participating in the trial.
: Not applicable.
: B. Fougère: consultancies, honoraria, advisory board, speakers: AstraZeneca, Bayer, Biogen, Biophitys, BMS, Boehringer-Ingelheim, CSL Vifor, GSK, MSD, Nestlé, Novartis, Pfizer.F. Puisieux: consultancies, honoraria, advisory board, speakers’ fees: Bayer, BMS, Boehringer-Ingelheim, CSL Vifor, GSK, MSD, Sanofi, Novartis, Pfizer.P. Chevalet: speaker’s fees for Vifor.C. Annweiler: no conflict of interest.E. Michel: no conflict of interest.L. Joly: no conflict of interest.F. Blanc: no conflict of interest.A. El Azouzi: no conflict of interest.V. Desré-Follet: employee of CSL Vifor, France.P. Cacoub: consultancies, honoraria, advisory board, speakers’ fees: Alnylam, Innotech, Mylan, Pfizer, Servier, and Vifor.
